Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
Year-over-year earnings per share growth rate
3Y CAGR
+99.0%/yr
vs +32.3%/yr prior
Acceleration
+66.7pp
Accelerating
Percentile
P97
Near historical high
vs 3Y Ago
7.9x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 860.00% |
| Q3 2025 | -53.45% |
| Q2 2025 | 420.31% |
| Q1 2025 | -20.99% |
| Q4 2024 | 14.08% |
| Q3 2024 | 1283.33% |
| Q2 2024 | 87.23% |
| Q1 2024 | -1211.11% |
| Q4 2023 | 112.82% |
| Q3 2023 | 13.16% |
| Q2 2023 | 52.50% |
| Q1 2023 | -900.00% |
| Q4 2022 | 109.09% |
| Q3 2022 | -37.50% |
| Q2 2022 | 50.00% |
| Q1 2022 | -23.08% |
| Q4 2021 | -8.33% |
| Q3 2021 | -50.00% |
| Q2 2021 | -134.78% |
| Q1 2021 | 309.09% |
| Q4 2020 | -30.95% |
| Q3 2020 | 19.23% |
| Q2 2020 | -182.54% |
| Q1 2020 | 222.33% |
| Q4 2019 | -49.28% |
| Q3 2019 | 43.90% |
| Q2 2019 | -11.82% |
| Q1 2019 | -678.95% |
| Q4 2018 | 113.57% |
| Q3 2018 | 11.39% |
| Q2 2018 | 4.82% |
| Q1 2018 | 7.26% |
| Q4 2017 | -26.06% |
| Q3 2017 | 8.97% |
| Q2 2017 | -15.56% |
| Q1 2017 | 14.56% |
| Q4 2016 | 33.33% |
| Q3 2016 | -58.00% |
| Q2 2016 | 21.05% |
| Q1 2016 | -35.71% |